Aptevo Therapeutics, Inc. (APVO)
1.87
-0.01
(-0.53%)
USD |
NASDAQ |
Sep 09, 16:00
1.80
-0.07
(-3.74%)
After-Hours: 17:07
Aptevo Therapeutics Total Assets (Quarterly) : 14.52M for June 30, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.52M |
| March 31, 2026 | 19.90M |
| December 31, 2025 | 27.99M |
| September 30, 2025 | 27.00M |
| June 30, 2025 | 15.62M |
| March 31, 2025 | 8.342M |
| December 31, 2024 | 15.59M |
| September 30, 2024 | 15.15M |
| June 30, 2024 | 14.92M |
| March 31, 2024 | 17.63M |
| December 31, 2023 | 24.84M |
| September 30, 2023 | 27.13M |
| June 30, 2023 | 28.91M |
| March 31, 2023 | 34.97M |
| December 31, 2022 | 34.22M |
| September 30, 2022 | 31.70M |
| June 30, 2022 | 38.80M |
| March 31, 2022 | 45.18M |
| December 31, 2021 | 56.60M |
| September 30, 2021 | 64.00M |
| June 30, 2021 | 71.47M |
| Date | Value |
|---|---|
| March 31, 2021 | 68.75M |
| December 31, 2020 | 53.55M |
| September 30, 2020 | 37.42M |
| June 30, 2020 | 18.51M |
| March 31, 2020 | 25.24M |
| December 31, 2019 | 53.41M |
| September 30, 2019 | 60.56M |
| June 30, 2019 | 66.13M |
| March 31, 2019 | 80.84M |
| December 31, 2018 | 67.49M |
| September 30, 2018 | 78.93M |
| June 30, 2018 | 90.00M |
| March 31, 2018 | 100.21M |
| December 31, 2017 | 117.01M |
| September 30, 2017 | 131.02M |
| June 30, 2017 | 86.89M |
| March 31, 2017 | 97.79M |
| December 31, 2016 | 91.86M |
| September 30, 2016 | 100.62M |
| June 30, 2016 | 118.16M |
| March 31, 2016 | 112.60M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 14.86M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 8.478M |
| Shareholders Equity (Quarterly) | 6.041M |
| Debt to Equity Ratio | 0.6967 |
| Current Ratio | 2.081 |
| Net Debt Paydown Yield | 0.68% |